ASCO 2015 Highlights

Real-world analysis of patients with MM determines treatment patterns and survival outcomes in patients with t(11;14) compared to patients with high- and standard-risk cytogenetics.

REGN5458, a BCMAxCD38 bispecific antibody, demonstrated early durable responses with a tolerable safety profile and low rates of CRS in patients with relapsed/refractory multiple myeloma.

Phase 2 results from MajesTEC-1 showed substantial clinical activity with teclistamab and are consistent with phase 1 findings.

Phase 1 data of ALLO-715 followed by lymphodepletion showed durable responses in heavily pretreated RRMM patients.

Results from cohort A of MagnetisMM-3 showed promising efficacy and a tolerable safety profile with elranatamab in RRMM patients naïve to BCMA-targeted treatment.

Results of patient-reported outcomes from the GRIFFIN study showed improved health-related quality of life in patients with NDMM with the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone.

A phase 2 study of isatuximab added to weekly carfilzomib, lenalidomide, and dexamethasone demonstrated promising efficacy and safety in transplant-eligible patients with newly diagnosed multiple myeloma.

Novel agent iberdomide demonstrated clinically meaningful activity and was generally well tolerated in a multicohort phase 1/2 trial.

Meta-analysis suggests that lenalidomide-carfilzomib may be the most effective maintenance treatment in patients with newly diagnosed multiple myeloma.

In the first trial with this treatment regimen, quadruplet induction with Isa-KRd in patients with high-risk MM demonstrated promising activity and a tolerable safety profile.